Grifols Launches a New Testing Service for Patients Treated with Daratumumab
- The Daratumumab neutralization testing service from Grifols, will allow improved management of patients under Daratumumab treatment requiring transfusion
- Test will be offered at Grifols Immunohematology Center in San Marcos, Texas
Barcelona (Spain), May 31th 2018.- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), one of the leading companies in the world in plasma-derived biological medicines and transfusion medicine, today announced it is adding a Daratumumab neutralization testing service to its extensive menu of services offered at Grifols Immunohematology Center laboratory (San Marcos, Texas). This new test facilitates complete antibody screening and identification in pretransfusion testing of patients under this therapy. The test is based on a soluble recombinant human CD38 that neutralizes the Daratumumab present in the plasma and eliminates its interferences with routine pretransfusion testing.
"This milestone is a testament to Grifols expertise in recombinant antigen research and development," said Carsten Schroeder, President, Grifols Diagnostic Division. "Continuing in our mission to deliver innovative transfusion medicine solutions, we are proud of this significant accomplishment that helps Daratumumab-treated patients receive better care."
Annually, there are more than 114,0001 new cases of multiple myeloma. Daratumumab, a monoclonal antibody for the treatment of multiple myeloma, targets a protein (CD38) that often manifests on multiple myeloma and immune cells. CD38 monoclonal antibodies can result in interference with routine pretransfusion testing which can cause delays in providing Red Blood Cell units to patients receiving these agents. In January 2016, the AABB Clinical Transfusion Medicine Committee issued a bulletin2 to provide background information and guidance on anti-CD38 interference, and recommendations for its prevention and treatment.
Immunohematologists screening patients treated with Daratumumab now have access to blood group genotyping and the neutralizing assay, facilitating red cell antigen typing and alloantibody identification (including antibodies to antigens of the Kell, Dombrock, or Indian blood group systems), overcoming the limitations of DTT pretreated Red Blood Cells. With this new solution, there is no need to provide K-negative units to patients and offers the option to save units for those patients who really need them.
Grifols Immunohematology Center, a CLIA reference laboratory, offers extensive testing capabilities, expert consulting, and classroom and laboratory-based educational programs for transfusion medicine professionals. The lab's main focus is on analyzing some of the most complex cases related to donor and patient blood typing, alloimmunization and newborn hemolytic disease.
To learn more about the Daratumumab neutralization testing service, additional services offered at Grifols Immunohematology Center, as well as other innovative diagnostic solutions, please visit Grifols booth at the 35th International Congress of the International Society for Blood Transfusion in Toronto, Canada on June 2-6, 2018 (booth #309) or visit Grifols website at www.diagnostic.grifols.com.